Literature DB >> 2511713

Low basal thyrotropin with normal thyroid function in primary hyperparathyroidism.

C Gillet1, P Bergmann, D Francois, J J Body, J Corvilain.   

Abstract

TSH serum levels and thyroid function in 32 patients with primary hyperparathyroidism and hypercalcemia were compared to those of 30 age and sex-matched normal subjects. Serum T3 and T4 concentrations in hyperparathyroidism were not different from normal. However, basal serum TSH concentrations measured with an ultrasensitive immunoradiometric assay were significantly lower than normal (1.09 +/- 0.49 vs 2.06 +/- 0.85 mU/l, p less than 0.001). In hyperparathyroidism, TSH, but not T4 or T3, was negatively correlated with serum calcium, not with iPTH. The increase in TSH (delta TSH) 30 min after the iv injection of TRH was also significantly blunted in patients with primary hyperparathyroidism; delta TSH was highly correlated with basal TSH in hypercalcemic patients. The basal TSH concentration was higher and no longer different from normal (1.70 +/- 1.2 mU/l) 2 to 12 months after removal of the parathyroid adenoma, when serum calcium was normalized, whereas T3 and T4 did not change. A low basal TSH with normal T4 and low T3 was found in 13 patients with hypercalcemia of malignancy. In these patients, TSH increased after treatment of hypercalcemia with 3-amino-l,hydroxypropylidene-1, 1-bisphosphonate, whereas T4 did not change. The results suggest that the set point of pituitary thyroid feedback control could be decreased in chronic hypercalcemia and that hypercalcemia could render the thyroid more sensitive to TSH.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511713     DOI: 10.1530/acta.0.1210638

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

1.  Hyperthyroxinemia after surgery for primary hyperparathyroidism.

Authors:  A Bergenfelz; B Ahrén
Journal:  Langenbecks Arch Chir       Date:  1994

2.  Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism.

Authors:  Mazhar Müslüm Tuna; Mustafa Çalışkan; Mustafa Ünal; Taner Demirci; Berçem Ayçiçek Doğan; Kerim Küçükler; Mustafa Özbek; Dilek Berker; Tuncay Delibaşı; Serdar Güler
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.